Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
PDS Biotechnology Corporation is a biotechnology business based in the US. PDS Biotechnology Corporation shares (PDSB) are listed on the NASDAQ and all prices are listed in US Dollars. PDS Biotechnology Corporation employs 15 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$11.58|
|52-week range||$1.87 - $17.85|
|50-day moving average||$14.91|
|200-day moving average||$10.45|
|Wall St. target price||$19.71|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.53|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-6.08%|
|1 month (2021-09-22)||-27.58%|
|3 months (2021-07-22)||12.10%|
|6 months (2021-04-22)||115.64%|
|1 year (2020-10-22)||421.62%|
|2 years (2019-10-22)||273.55%|
|3 years (2018-10-22)||1,444.00%|
|5 years (2016-10-21)||6.63%|
|Gross profit TTM||$0|
|Return on assets TTM||-20.63%|
|Return on equity TTM||-25.71%|
|Market capitalisation||$350.5 million|
TTM: trailing 12 months
There are currently 489,087 PDS Biotechnology Corporation shares held short by investors – that's known as PDS Biotechnology Corporation's "short interest". This figure is 10.2% up from 443,869 last month.
There are a few different ways that this level of interest in shorting PDS Biotechnology Corporation shares can be evaluated.
PDS Biotechnology Corporation's "short interest ratio" (SIR) is the quantity of PDS Biotechnology Corporation shares currently shorted divided by the average quantity of PDS Biotechnology Corporation shares traded daily (recently around 489087). PDS Biotechnology Corporation's SIR currently stands at 1. In other words for every 100,000 PDS Biotechnology Corporation shares traded daily on the market, roughly 1000 shares are currently held short.
However PDS Biotechnology Corporation's short interest can also be evaluated against the total number of PDS Biotechnology Corporation shares, or, against the total number of tradable PDS Biotechnology Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PDS Biotechnology Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 PDS Biotechnology Corporation shares in existence, roughly 20 shares are currently held short) or 0.0195% of the tradable shares (for every 100,000 tradable PDS Biotechnology Corporation shares, roughly 20 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against PDS Biotechnology Corporation.
Find out more about how you can short PDS Biotechnology Corporation stock.
We're not expecting PDS Biotechnology Corporation to pay a dividend over the next 12 months.
PDS Biotechnology Corporation's shares were split on a 1:20 basis on 17 March 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your PDS Biotechnology Corporation shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for PDS Biotechnology Corporation shares which in turn could have impacted PDS Biotechnology Corporation's share price.
Over the last 12 months, PDS Biotechnology Corporation's shares have ranged in value from as little as $1.87 up to $17.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PDS Biotechnology Corporation's is 2.0048. This would suggest that PDS Biotechnology Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U. S. Department of Health and Human Services, and MSD International GmbH.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.